Drug Type Small molecule drug |
Synonyms Isuzinaxib Hydrochloride + [1] |
Target |
Mechanism NOX inhibitors(NADPH oxidase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC17H17N3O |
InChIKeyLQKQLKMTJOMCMJ-UHFFFAOYSA-N |
CAS Registry1270084-92-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | US | 20 Oct 2021 | |
Diabetes Mellitus, Type 2 | Phase 3 | RS | 24 Aug 2020 | |
Diabetes Mellitus, Type 2 | Phase 3 | BG | 24 Aug 2020 | |
Diabetes Mellitus, Type 2 | Phase 3 | CZ | 24 Aug 2020 | |
Diabetes Mellitus, Type 2 | Phase 3 | HU | 24 Aug 2020 | |
Mandibuloacral Dysplasia With Type a Lipodystrophy | Phase 3 | FR | 28 May 2018 | |
Seasonal Affective Disorder | Phase 3 | FR | 28 May 2018 | |
Acute Kidney Injury | Phase 2 | KR | 27 Dec 2023 | |
Acute Kidney Injury | Phase 2 | US | 27 Dec 2023 | |
Diabetic Nephropathies | Phase 2 | - | - |
NCT04534439 (ASN2022) Manual | Phase 2 | 140 | (zlujibkass) = gfmdmwlrce ckaakqnexl (bpinfcjhqm ) View more | Positive | 04 Nov 2022 | ||
Placebo | (zlujibkass) = nipkvocgxw ckaakqnexl (bpinfcjhqm ) View more |